Aripiprazole

Generic Name
Aripiprazole
Brand Names
Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
Drug Type
Small Molecule
Chemical Formula
C23H27Cl2N3O2
CAS Number
129722-12-9
Unique Ingredient Identifier
82VFR53I78
Background

Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A ...

Indication

Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation as...

Associated Conditions
Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
Associated Therapies
Monotherapy
Clinical Trials
Related News

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

First Posted Date
2006-07-04
Last Posted Date
2008-05-21
Lead Sponsor
Solvay Pharmaceuticals
Target Recruit Count
286
Registration Number
NCT00347425
Locations
🇺🇸

Site 180, Kenilworth, New Jersey, United States

🇦🇷

Site 308, Mendoza, Argentina

🇭🇺

Site 212, Gyor, Hungary

and more 119 locations

Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia

First Posted Date
2006-06-27
Last Posted Date
2014-06-23
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
38
Registration Number
NCT00345033
Locations
🇺🇸

Massachusetts General Hospital Schizophrenia Program, Boston, Massachusetts, United States

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

Phase 3
Withdrawn
Conditions
Bipolar Disorder
Interventions
Drug: Aripiprazole
Drug: Placebo
First Posted Date
2006-06-20
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Registration Number
NCT00338273
Locations
🇮🇳

Local Institution, Vishakhapatnam, India

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

First Posted Date
2006-06-16
Last Posted Date
2013-12-02
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
218
Registration Number
NCT00337571
Locations
🇺🇸

Cambridge Health Alliance, Medford, Massachusetts, United States

🇺🇸

Clinical Innovations, Inc., Huntington Beach, California, United States

🇺🇸

University Of Florida, Gainesville, Florida, United States

and more 28 locations

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Phase 3
Completed
Conditions
Autistic Disorder
Interventions
Drug: Placebo
Drug: Aripiprazole
First Posted Date
2006-06-01
Last Posted Date
2013-12-02
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
98
Registration Number
NCT00332241
Locations
🇺🇸

Univ Of Nc, Chapel Hill, North Carolina, United States

🇺🇸

Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States

🇺🇸

Marsella, Gregory, Boca Raton, Florida, United States

and more 6 locations

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

First Posted Date
2006-05-29
Last Posted Date
2018-07-10
Lead Sponsor
Northwell Health
Target Recruit Count
357
Registration Number
NCT00330863
Locations
🇺🇸

University of California, Los Angeles, Los Angeles, California, United States

🇺🇸

Medical College of Georgia, Department of Psychiatry, Augusta, Georgia, United States

🇺🇸

Harvard Medical School -- Dr. John C. Corrigan Community Mental Health Center, Fall River, Massachusetts, United States

and more 5 locations

Effect on Cognitive Function of a Treatment With Aripiprazole

Phase 4
Completed
Conditions
Schizophrenia
Interventions
Drug: Aripiprazole
First Posted Date
2006-05-25
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
500
Registration Number
NCT00329810

Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia
Interventions
Drug: aripiprazole
Drug: placebo
First Posted Date
2006-05-19
Last Posted Date
2008-10-29
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
61
Registration Number
NCT00328367
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder

Phase 1
Completed
Conditions
Bipolar Disorder
Interventions
Drug: aripiprazole
First Posted Date
2006-05-03
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
20
Registration Number
NCT00321516
Locations
🇺🇸

Local Institution, Desota, Texas, United States

Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis

Phase 4
Completed
Conditions
Schizophrenia
Interventions
Drug: Aripiprazole
Drug: Risperidone
First Posted Date
2006-05-03
Last Posted Date
2016-09-08
Lead Sponsor
Northwell Health
Target Recruit Count
198
Registration Number
NCT00320671
Locations
🇺🇸

The Zucker Hillside Hospital, Glen Oaks, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy